ADMA Biologics, Inc.

NasdaqGM ADMA

ADMA Biologics, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 231.89 M

ADMA Biologics, Inc. Shareholders' Equity is USD 231.89 M for the quarter ending September 30, 2024, a 53.13% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

ADMA Biologics, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 151.44 M, a 50.86% change year over year.
ADMA Biologics, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 100.38 M, a -2.33% change year over year.
ADMA Biologics, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 102.78 M, a 44.00% change year over year.
ADMA Biologics, Inc. Shareholders' Equity for the quarter ending September 30, 2020 was USD 71.38 M, a 97.62% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: ADMA

ADMA Biologics, Inc.

CEO	Mr. Adam S. Grossman
IPO Date	Oct. 17, 2013
Location	United States
Headquarters	465 State Route 17
Employees	624
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pharmaceuticals Tobacco Vaccines

Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Key trends

Past 5 years